Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Entertainment
  • Real Estate
  • Business
  • Technology
  • Artificial Intelligence
  • Non-profit
ncarol.com

OncoBeta introduces Rhenium-SCT for non-melanoma skin cancer patients at Hospital Universitario 12 de Octubre
ncarol.com/10264760

Trending...
  • LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Law Offices of Larry E. Bray, P.A. Wins Fourth District Appeal Clarifying Limits of Florida's Offer of Judgment Statute
OncoBeta team stand with the treating physicians Patient undergoing treatment with Rhenium-SCT
MADRID - ncarol.com -- OncoBeta®, a leading medical device company specialising in innovative epidermal radioisotope therapies, today announced Hospital Universitario 12 de Octubre, in Madrid, has treated its first patient with Rhenium-SCT® (skin cancer therapy) – and is expected to continue offering this therapy for patients with non-melanoma skin cancers (NMSCs).

Rhenium skin cancer therapy is an advanced radionuclide therapy technology that offers a painless,*1,2 single-session,†1-3 non-invasive‡1 treatment without disfiguring scarring.1,4 Treatment with Rhenium-SCT employs a superficial application of a paste containing β-emitting particles directly to the NMSC lesion, targeting cancer cells without the need for surgery.1,4

Shannon D. Brown III, CCO at OncoBeta, says, "With rates of NMSC increasing globally, we feel it's vitally important that new treatment options are offered to patients. Surgical intervention continues to be the most common treatment, but it can lead to disappointing results. Rhenium skin cancer therapy addresses many patients' desires for a non-surgical alternative – with simple application directly to the lesion, treatment time generally ranges 45 to 180 mins, which means patients can continue with their lives with very little disruption."

New cases of NMSCs in Spain are expected to almost double from 2022-2050 according to latest figures by the International Agency of Research on Cancer as part of the World Health Organization,5 making Mardrid an important location for this innovative NMSC treatment option.

"Rhenium-SCT has long been accessible to patients across Europe. This new clinic in Spain marks a significant milestone in expanding access to this innovative treatment for non-melanoma skin cancer patients," Mr Brown explains.

Dr Gerhard Dahlhoff, Medical Director at OncoBeta, says, "Rhenium-SCT allows for a targeted and non-invasive treatment of NMSCs without damaging adjacent healthy tissue. It offers a patient-friendly treatment alternative and we are delighted to have another medical facility offering Rhenium-SCT to those suffering with NMSCs".

More on ncarol.com
  • 10 Subpoenas in Mountain BizWorks Suit Probe Exposed Loan Data, Deleted Records, and Retaliation
  • NANNNA Shines in Stamford: The Men Who Came to Support Their Wives
  • Aoolia Offers Free Virtual Try On Glasses for 1,500+ Frames Using Just a Phone Camera
  • Education Through Music-LA Honors Grammy-Winning Pitch Perfect Music Supervisors Julianne Jordan & Julia Michels, Educator Anthony "Tony" White
  • TOKSTAR Welcomes NBA 2K Star Young Wayne

___

About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.1 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.1,4

The Rhenium-SCT is a painless,*1,2  single session,†1-3 non-invasive‡1 therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.1,4,6 The Rhenium-SCT utilizes the radioisotope rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalized therapy that is only applied to the area needed to treat without affecting the healthy tissue.4,6 The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (basal cell carcinomas and squamous cell carcinomas) can be treated using the Rhenium-SCT in one single session. †1-4 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.1,6,7

About OncoBeta®
OncoBeta® with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.

Find out more about the Rhenium-SCT at www.oncobeta.com

More on ncarol.com
  • Matt Zavala of Zavala Law, PC Elected to Ventura County Bar Association Board of Directors
  • Bryan Regan Photography shoots for GQ Magazine
  • Montana Artist Ryan Jolley Receives Goodman Award at Mountain Oyster Club Art Show
  • Make Your Move to Luxury Living at Heritage at Hopewell with Rates Starting at Just 3.750% (5.803% APR)
  • Scott Glickson Joins STS Capital Partners as Managing Director

Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

*No reported pain during procedure.1,2
†
Complete tumour regression in 98.5% of lesions treated.3
‡
A treatment is considered non-invasive when no cut or break in the skin is created.8

References
  1. Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021; 48: 1511–1521.
  2. Cipriani C, et al. J Dermatol Treat. 2022;33(2):969–975. Epub 22 Jul 2020.
  3. Cipriani C, et al. In Therapeutic Nuclear Medicine. 2014. RP Baum (Ed), New York: Springer.
  4. Tietze JK, et al. Clin Nucl Med. 2023;48:869–76.
  5. Global Burden of Disease Cancer Collaboration, et al. JAMA Oncol. 2019;5(12):1749-1768.
  6. Cipriani C, et al. International J Nucl Med. 2017; July:114–112.
  7. Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745–749.
  8. Australian Therapeutic Goods Administration. Acronym and glossary of terms. Available at: https://www.tga.gov.au/resources/acronyms-and-glossary-terms. (Accessed June 2024).


Contact
Jane Morey
***@moreymedia.com.au


Source: OncoBeta GmbH

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
  • Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West
  • The Seaside Art Gallery Presents
  • Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
  • Asheville-Based KayeDinero Surpasses 100-Track Goal as Detroit Lions Win 35-10 in Munich
  • Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
  • Nious Media Expands Gaming Coverage With 2026 Game & Geek Expo Special
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • The Dark Chocolate Nutcracker Marks 15 Years
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
  • After Nvidia's 14% Drop, Asheville Artist KayeDinero Releases "Nvidia"
  • LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
_catLbl0 _catLbl1

Popular on ncarol.com

  • Nious Media Expands Independent Entertainment Network Through Gaming, Music and Digital Storytelling - 235
  • Kestrel Ridge Health Launches AI-Powered Ophthalmology Workforce Forecasting Platform - 235
  • North Carolina Author Carrie Sybert Celebrates Three Published Books - 206
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki - 144
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs - 133
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration - 129
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA) - 124
  • Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers - 124
  • New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight - 115
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position - 114

Similar on ncarol.com

  • Ella Langley Hits the 2026 CMA Awards Red Carpet in Custom KmXtend Clip-In Extensions Styled by Chris Bear
  • NANNNA Shines in Stamford: The Men Who Came to Support Their Wives
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute